Bone Biologics Corp Files 8-K on Officer/Director Changes
Ticker: BBLGW · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: BBLG
TL;DR
BBLG filed an 8-K: leadership changes and compensation updates effective Oct 16.
AI Summary
Bone Biologics Corporation filed an 8-K on October 21, 2024, reporting events as of October 16, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensation adjustments, can signal internal shifts that may affect future performance.
Key Players & Entities
- Bone Biologics Corporation (company) — Filer of the 8-K report
- October 16, 2024 (date) — Earliest event date reported
- October 21, 2024 (date) — Date of report filing
FAQ
What specific officer or director positions were affected by the changes reported in the 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided text.
Are there any details about new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specifics of these arrangements are not provided in the excerpt.
What is the significance of the 'Financial Statements and Exhibits' being included in this 8-K filing?
Including financial statements and exhibits suggests that these changes are accompanied by financial reporting or supporting documentation relevant to the reported events.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 16, 2024.
What is the SIC code for Bone Biologics Corp?
The Standard Industrial Classification (SIC) code for Bone Biologics Corp is 3842, which corresponds to 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES'.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-10-21 08:05:21
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex99-1.htm (EX-99.1) — 12KB
- logo_001.jpg (GRAPHIC) — 103KB
- 0001493152-24-041710.txt ( ) — 426KB
- bblg-20241016.xsd (EX-101.SCH) — 4KB
- bblg-20241016_def.xml (EX-101.DEF) — 29KB
- bblg-20241016_lab.xml (EX-101.LAB) — 36KB
- bblg-20241016_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Bone Biologics Corporation, dated October 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: October 21, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer